Deep mutational scanning identifies SARS-CoV-2 Nucleocapsid escape mutations of currently available rapid antigen tests

Cell. 2022 Sep 15;185(19):3603-3616.e13. doi: 10.1016/j.cell.2022.08.010. Epub 2022 Aug 29.

Abstract

The effects of mutations in continuously emerging variants of SARS-CoV-2 are a major concern for the performance of rapid antigen tests. To evaluate the impact of mutations on 17 antibodies used in 11 commercially available antigen tests with emergency use authorization, we measured antibody binding for all possible Nucleocapsid point mutations using a mammalian surface-display platform and deep mutational scanning. The results provide a complete map of the antibodies' epitopes and their susceptibility to mutational escape. Our data predict no vulnerabilities for detection of mutations found in variants of concern. We confirm this using the commercial tests and sequence-confirmed COVID-19 patient samples. The antibody escape mutational profiles generated here serve as a valuable resource for predicting the performance of rapid antigen tests against past, current, as well as any possible future variants of SARS-CoV-2, establishing the direct clinical and public health utility of our system.

Keywords: SARS-CoV-2 Nucleocapsid protein; antibodies; deep mutational scanning; epitope mapping; mammalian surface-display; rapid diagnostic tests; variants.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19*
  • Epitopes / genetics
  • Humans
  • Mammals
  • Mutation
  • Nucleocapsid
  • SARS-CoV-2* / genetics

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Epitopes